Bone Biologics Corp
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
BBLG$0.33+3.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Deficit
Consolidated Statement of Stockholders’ Equity(1)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 89,127 | $89 | $83,815,230 | $(80,908,958) | $2,906,361 |
| Fair value of vested stock options | - | - | 188,819 | - | 188,819 |
| Options issued to settle accrued bonus | - | - | 77,400 | - | 77,400 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs of $495,227 | 19,833 | 20 | 1,504,093 | - | 1,504,113 |
| Exercise of pre-funded warrants | 110,376 | 110 | 552 | - | 662 |
| Issuance of common shares from warrant inducement, net of costs of $287,233 | 130,208 | 130 | 1,806,390 | - | 1,806,520 |
| Incremental value of warrant inducement | - | - | 3,212,504 | - | 3,212,504 |
| Deemed dividend on warrant inducement | - | - | (3,212,504) | - | (3,212,504) |
| Issuance of common shares from ATM, net of costs of $205,256 | 142,873 | 143 | 1,112,059 | - | 1,112,202 |
| Net Loss | - | - | - | (4,112,420) | (4,112,420) |
| Balance at December 31, 2024 | 492,417 | 492 | 88,504,543 | (85,021,378) | 3,483,657 |
| Fair value of vested stock options | - | - | 256,358 | - | 256,358 |
| Options issued to settle accrued bonus | - | - | 46,183 | - | 46,183 |
| Issuance of common shares from ATM, net of costs of $13,029 | 52,843 | 53 | 347,496 | - | 347,549 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs of $647,208 | 793,750 | 794 | 4,351,998 | - | 4,352,792 |
| Exercise of pre-funded warrants | 456,250 | 456 | (456) | - | - |
| Net Loss | - | - | - | (3,108,991) | (3,108,991) |
| Balance at December 31, 2025 | 1,795,260 | $1,795 | $93,506,122 | $(88,130,369) | $5,377,548 |
| (1) | Adjusted to reflect the reverse stock split as described in Note 1. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.